Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Pamorelin 11.25 mg subcutaneous vs intramuscular in advanced prostate cancer
2005-005058-31Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Jul 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Pamorelin in prostate cancer (PCa) (2 arms), sponsored by Ipsen. Primary endpoint: Castration-level testosterone at week 24. Started Jul 2006; status: terminated.
02
Drugs
Pamorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005058-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005058-31.